103 results about "Low-density lipoprotein" patented technology

The disclosure provides methods of identifying a subject for treatment with an anti-ox-LDL antibody. The disclosure also provides methods of treating a subject with an anti-ox-LDL antibody, wherein the subject has been identified to as a candidate for anti-oxLDL antibody therapy. The methods described herein use computed tomography to identify subjects who are a candidate for anti-oxLDL antibody therapy, wherein a subject may be determined to be a candidate for anti-oxLDL antibody therapy by evaluating their fat attenuation index (FAI), perivascular adipose tissue (PVAT), pericoronary adipose tissue, FAI score, FAI percentile, or CaRi-Heart® Risk score.

Relating to the technical field of gene therapy, provided is an siRNA molecule for inhibiting PCSK9 expression, and use thereof. Particularly, an siRNA molecule for inhibiting PCSK9 expression (comprising a sense strand and an anti-sense strand that are complementary to form a double-stranded region) and a pharmaceutical composition comprising the same are disclosed. The siRNA molecule has a high silencing efficiency and a long-lasting silencing effect for PCSK9 gene, and is useful in the manufacture of products for inhibiting PCSK9 protein expression, products for reducing the concentration of low-density lipoprotein or low-density lipoprotein cholesterol in serum; and products for relieving the symptoms of PCSK9 gene-mediated diseases.

The disclosure provides methods of reducing the risk of a major adverse cardiovascular event (MACE) in a subject having previously experienced acute coronary syndrome (ACS) and for reducing risk of a MACE in a patient who is diagnosed with coronary artery disease and has blood high-sensitivity C- reactive (hs-CRP) of >2.0 mg / L. The methods include administering to the subject an anti-oxLDL antibody. The anti-oxLDL antibody may be administered to the subject alone or in combination with one or more additional therapeutic agents, such as one or more lipid lowering agents.

The invention belongs to the technical field of biological medicines, and particularly relates to application of a macrophage Angulin-1 gene and / or an Angulin-1 protein in preparation of medicines and diagnostic products for preventing and / or treating atherosclerosis and related diseases. Research finds that plaque and necrotic core areas of an atherosclerosis animal model are remarkably increased due to macrophage Angulin-1 gene knockout, and disease development is promoted; and the recovery of the expression level of Angulin-1 significantly inhibits the development of lesion. Cell experiments show that Angulin-1 reduces intake of oxidized low-density lipoprotein by down-regulating expression of macrophage LOX-1, so that formation of foam cells is inhibited. Therefore, the macrophage Angulin-1 can be used as an atherosclerosis drug target, a gene therapy target gene and an auxiliary diagnosis marker, and a new theoretical basis and an intervention strategy are provided for prevention and treatment of the disease.

The invention provides a construction method and application of a blood sinus networked liver organ. According to the method, pluripotent stem cells are co-differentiated into HAND1 < + > mesoderm and endoderm, a front intestine rear endoderm containing KDR < + > mesoderm progenitor cells is generated, a liver endoderm with CD34 < + > / CD31 < + > endothelial progenitor cells is generated, and the blood sinus networked liver organ is formed. The liver organ has a functional blood sinus endothelial network penetrating through the liver cluster, and has the characteristic functions of low-density lipoprotein uptake, human serum albumin removal, mediated secretion of blood coagulation factor 8 and the like. The method provides a new-generation highly bionic research tool for liver disease mechanism analysis, drug screening and regeneration repair.

The present disclosure, in some aspects, relates to antisense oligonucleotides (ASO) for use in the prevention or treatment of a disease or a condition associated with low- density lipoprotein (LDL) in a subject. In some embodiments, the ASO effects site-directed adenosine-to-inosine (A-to-l) editing of a target adenosine in a target RNA sequence derived from a sequence of an endogenous low-density lipoprotein receptor (LDLR) gene such that: a) the modified LDLR protein has: (i) reduced binding to the inducible degrader of the LDLR protein (IDOL); (ii) increased stability; (iii) improved resistance to IDOL-mediated degradation; (iv) increased LDLR protein expression; and / or (v) increased activity or function to take up LDL; and / or b) editing of the 3'-untranslated region (UTR) of the target RNA leads to an increase in LDLR protein expression and / or stability.

Disclosed is a strain of Bifidobacterium longum subsp. longum named dipro-O. The Bifidobacterium longum subsp. longum dipro-O used in the present invention has the ability to overproduce BSH, the ability to reduce cholesterol, and the ability to metabolize tryptophan into indole-3-lactic acid, can effectively reduce body weight, significantly lower insulin resistance levels resulting from high-fat diets, reduce the expression of the inflammatory cytokine TNF-α, significantly lower the levels of total cholesterol (TC) and low-density lipoprotein (LDL) in the blood, and increase the level of high-density lipoprotein (HDL), and can ameliorate disorders of the gut microbiome structure. In addition, the strain can also have an ameliorating effect on other lipid metabolism-related diseases such as hyperlipidemia, thereby providing health interventions for the host's body weight, liver, intestinal health, and blood lipid levels. Moreover, pasteurized dipro-O can also have the effect of regulating lipid metabolism, further extending the range of applications of the strain.

The invention provides an application of streptococcus salivarius in fatty liver, in particular to an application of streptococcus salivarius in preparation of a product, and the product is used for at least one of the following applications: (a) losing weight or reducing body fat; (b) improving the glucose tolerance of the patient; (c) increasing the sensitivity of the patient to insulin; (d) treating, relieving and preventing liver injury; (e) treating, relieving and preventing non-alcoholic steatohepatitis; (f) fat deposition caused by high-fat and high-cholesterol diet is reduced; (g) reducing blood fat; and / or (h) improving the level of at least one of the following indexes in the liver of the mammal: total cholesterol, triglyceride, low density lipoprotein-cholesterol and free fatty acid.

The invention relates to a probiotic preparation containing a BL11 strain and capable of improving obesity-related metabolism and senescence indexes of middle-aged and elderly people and application of the probiotic preparation. The strain in the probiotic preparation is composed of a bifidobacterium longum subsp. Longum BL11 strain and a pediococcus acidilactici PA53 strain. The two strains can cooperate with each other and promote each other, and have a synergistic effect in the aspect of improving obesity-related metabolic indexes, which is specifically embodied in that: the weight increase and body fat rate of mice fed with high fat diet can be reduced; the low-density lipoprotein level, the total cholesterol level and the triglyceride level are reduced, and the high-density lipoprotein level is improved; fasting blood-glucose, glycosylated hemoglobin level and insulin resistance index are reduced; chronic inflammation is relieved; meanwhile, the composition also has excellent performance in the aspect of improving senescence-related indexes, the content of malondialdehyde in serum can be reduced, the activity of superoxide dismutase and glutathione peroxidase can be improved, and the activity of telomerase can be improved.

Provided are a method of assisting the detection of nonalcoholic steatohepatitis (NASH) and a method that is able to assist in determining the degree of progression of any condition associated with NASH, which are far less invasive than liver biopsy and include simple operations and are independent of the skills of technicians.The present invention provides a method of assisting the detection of nonalcoholic steatohepatitis, including measuring the abundance of LDL-TG and / or ApoE-rich HDL-C contained in a test blood sample isolated from a living body. Also, the present invention provides a method of assisting in determining the degree of progression of at least one medical condition associated with nonalcoholic steatohepatitis, which medical condition(s) is(are) selected from the group consisting of fatty degeneration (steatosis), inflammation, ballooning degeneration, and fibrosis, including measuring the abundance of LDL-TG and / or ApoE-rich HDL-C contained in a test blood sample isolated from a living body.

The invention discloses a composition with an auxiliary blood fat reducing effect as well as a preparation method and application thereof, and relates to the technical field of medicines. In the composition disclosed by the invention, the hawthorn, the lotus leaf, the mulberry leaf and the algae oil are mutually matched for use and have a synergistic effect, so that the effects of remarkably reducing the body weight, reducing the content of low-density lipoprotein, the content of Apo-B and the content of GLU in blood and improving indexes of high-density lipoprotein and Apo-A1 are achieved. The composition is applied to preparation of the blood fat reducing medicine and / or health food, and the blood fat reducing effect is stable.

The present invention relates to a Korean microbiome-derived Clostridium butyricum strain having anti-obesity efficacy and a use thereof. The strain has an excellent effect of reducing the body weight and adipose tissue weight of experimental animals compared to a control group (strain-untreated) under high-fat diet conditions, has an excellent effect of reducing the content of total cholesterol, triglycerides, low-density lipoprotein (LDL), leptin, alanine aminotransferase (ALT), and aspartate aminotransferase (AST) in serum, and has an excellent effect of reducing blood glucose and increasing the content of glucagon-like peptide-1 (GLP-1) in an oral glucose load test, and is thus expected to be effectively used as an ingredient in a composition for preventing, alleviating, or treating obesity and metabolic diseases caused by obesity.

The invention belongs to the technical field of biological detection, and particularly relates to a detection method and a detection kit for oxidized low-density lipoprotein. The invention provides a novel application of quaternary ammonium salt chitosan in a kit, and particularly relates to application of quaternary ammonium salt chitosan with different molecular weights in an immunoturbidimetry detection process of oxidized low-density lipoprotein. When high-molecular-weight quaternized chitosan with the molecular weight of 100-200 kDa and low-molecular-weight quaternized chitosan with the molecular weight of 30-50 kDa are used as components of the oxidized low-density lipoprotein detection kit, the quaternized chitosan with different molecular weights can react with citrate radicals to form gel particles with different mechanical strengths; the content of the oxidized low-density lipoprotein can be detected through immunoturbidimetry, and the sensitivity and the linear range of the oxidized low-density lipoprotein detection kit are greatly improved and widened by using the quaternized chitosan with different molecular weights.

The invention belongs to the technical field of medical materials, and particularly relates to an adsorption material for removing low-density lipoprotein as well as a preparation method and application of the adsorption material. The adsorption material comprises a carrier and a ligand immobilized on the carrier, wherein the carrier is obtained by grafting and modifying polymer microspheres through glycidyl methacrylate, and the polymer microspheres comprise at least one of polystyrene divinyl benzene resin microspheres and polymethacrylate resin microspheres; the ligand contains a group with negative electricity.

Compositions and methods for treating rheumatoid arthritis and / or accelerated atherosclerosis are provided, including an inhibitor of oxidized or malondialdehyde-modified low density lipoprotein (LDL) for administration to a subject. Exemplary inhibitors of oxidized LDL include an anti-oxidized LDL antibody, which results in a reduction in the secretion of pro-inflammatory cytokine from primary monocyte in vitro and the plasma cytokine level of inflammatory cytokine in vivo.

A hypercholesterolemic profile of a patient is determined on the basis of (i) a first statistical distribution based on a scale of polygenic risk score levels and a scale of cholesterol concentration levels in low-density lipoproteins, the first statistical distribution giving, based on these scales, a distribution of individuals in a first sub-sample of severely hypercholesterolemic individuals having at least one genetic mutation causing hypercholesterolemia for at least one gene from a set of genes and (ii) a second statistical distribution based on the same scale of polygenic risk score levels and the same scale of cholesterol concentration levels in low-density lipoproteins,the second statistical distribution giving, as a function of these scales, a distribution of individuals from a second sub-sample of severely hypercholesterolemic individuals not presenting a genetic mutation in the set of genes;

The invention belongs to the technical field of medicines, and particularly relates to application of urolithin A and beta-nicotinamide mononucleotide in preparation of a medicine for treating diabetes. The invention finds that when the urolithin A and the beta-nicotinamide mononucleotide are independently used, the hypoglycemic effect on diabetic mice cannot be realized, and when the urolithin A and the beta-nicotinamide mononucleotide are jointly used, the symptoms of diabetes and insulin resistance caused by high fat diet can be remarkably improved; the glucose tolerance and the insulin tolerance are improved; meanwhile, the content of low-density lipoprotein and cholesterol in a mouse body is reduced, so that the risk of thrombus occurrence is reduced; in addition, combined medication can significantly reduce liver cell lipid accumulation and improve mitochondrial morphological abnormality. The invention provides a brand new technical scheme and experimental basis for treating diabetes caused by high fat diet and relieving insulin resistance, and has important medical application value.

This invention belongs to the field of traditional Chinese medicine technology. More specifically, it relates to the application of a processed product of Citrus reticulata peel or Citrus reticulata peel embryo (with bitterness removed) in the preparation of products for lowering lipids and preventing and treating hyperlipidemia. Compared with the original product, the processed product of Citrus reticulata peel or Citrus reticulata peel embryo provided by this invention significantly reduces bitterness while significantly enhancing its effects in lowering cholesterol and triglycerides and regulating blood lipids. This processed product helps maintain normal levels of serum cholesterol, triglycerides, and low-density lipoprotein, and can significantly improve liver damage caused by hyperlipidemia, thus having important application value in lowering lipids and protecting the liver.

The application belongs to the technical field of traditional Chinese medicine exosomes, and particularly relates to mulberry-derived extracellular vesicle particles, a preparation method thereof and application thereof in the preparation of medicines for preventing and treating hyperlipidemia and related symptoms. The mulberry-derived extracellular vesicle particles provided by the application are prepared by using mulberries as raw materials, centrifuging the mulberries at different centrifugal speeds after juice extraction, and then performing density gradient centrifugation with a sucrose solution with a specific density. Experimental research shows that the mulberry-derived extracellular vesicle particles can significantly reduce total cholesterol, triglyceride and low-density lipoprotein in blood, inhibit the formation of aortic plaques caused by hyperlipidemia and lipid deposition in the liver, and are safe and non-toxic, and therefore can be used for the preparation of medicines for preventing and treating hyperlipidemia and related symptoms.

The application discloses a composition for improving blood lipid metabolism, which comprises the following raw materials: sweet cinnamon powder, rhodiola powder, roxburgh rose powder and curcuma zedoaria powder. The preparation method of the composition for improving blood lipid metabolism comprises the following steps: screening the sweet cinnamon powder, the rhodiola powder, the roxburgh rose powder and the curcuma zedoaria powder respectively, mixing them uniformly to obtain mixed powder; adding sterile deionized water into the mixed powder to obtain a mixed solution; adding a complex enzyme into the mixed solution for enzymolysis; after the enzymolysis is completed, the enzyme is inactivated, filtration is conducted, and the filtrate is freeze-dried to obtain the composition for improving blood lipid metabolism. The plant powder is subjected to mixed enzymolysis through multiple enzymes, the natural active substances in the plant powder are enriched, and the types of the enzymolysis products are enriched, so that the total cholesterol, the triglyceride and the low-density lipoprotein content in blood can be reduced, and the high-density lipoprotein content in blood can be increased.

The present invention relates to a composition for alleviating obesity or improving lipid metabolism, comprising a Rostellularia procumbens extract. The Rostellularia procumbens extract according to the present invention has the effects of inhibiting weight gain and fat accumulation and lowering blood levels of total triglycerides, total cholesterol, and low-density lipoprotein. In addition, the Rostellularia procumbens extract of the present invention, as a natural medicinal agent, can be applied to various products such as pharmaceutical compositions, food compositions, and feed compositions for the prevention, treatment, or alleviation of obesity or for the improvement of lipid metabolism.

This invention discloses a method for preparing filler particles for targeted adsorption of low-density lipoprotein (LDL) in patients with atherosclerosis. The steps include: 1) washing D101 macroporous resin with ultrapure water and physiological saline; 2) adding fibrin and PBS solution for soaking; adding thrombin factor II; adding zinc gluconate during the reaction; 3) repeating step 2) at least three times and drying the D101 macroporous resin; 4) adding physiological saline and D101 macroporous resin to lyophilized protein ApoB100 and mixing thoroughly; 5) lyophilizing the resin obtained in step 4) while controlling the humidity at 65±5% to obtain the finished product. This application utilizes this adhesion effect to target the adsorption of foam cells in atherosclerosis, adsorbing foam cells through hemoperfusion, removing redundant blood lipid components in the body, reducing macrophage infiltration of organs and blood vessels, and reducing pathological changes in organs and blood vessels.

The application belongs to the technical field of diagnostic markers, and particularly relates to a pathological diagnosis biomarker combination for adrenal Cushing syndrome and application. The pathological diagnosis biomarker combination comprises low density lipoprotein receptor (LDLR), 3-hydroxy-3-methylglutaryl coenzyme A synthetase 1 (HMGCS1) and cytochrome P450 11B1 (CYP11B1). The area under the ROC curve (AUC) of the pathological diagnosis biomarker combination can reach 0.881 (95% confidence interval (CI): 0.775-987; sensitivity: 85.7%; specificity: 85.0%), which indicates that the combination of LDLR, HMGCS1 and CYP11B1 as the pathological diagnosis biomarker combination for adrenal Cushing syndrome has high accuracy.

A method for preparing immune effector cells for transduction, comprising a step for increasing expression of low density lipoprotein receptor (LDLR) and, optionally, a step for inhibiting intracellular antiviral defense mechanisms of the immune effector cells.

The invention discloses a preparation method and application of cannabis sativa peptide with effects of reducing blood fat and adjusting lipid metabolism, belongs to the technical field of biology, and has a wide application prospect. The fructus cannabis peptide obtained by the technical scheme and the preparation method disclosed by the invention has the following effects: 1, the fructus cannabis peptide prepared by the preparation method disclosed by the invention can be used for remarkably improving pancreatic lipase activity (the highest inhibition rate can reach 65.0%), so that digestion and absorption of a human body on lipid substances such as animal and vegetable oil and cholesterol are blocked; 2, the cannabis sativa peptide prepared by the preparation method disclosed by the invention can be used for remarkably improving the abnormality of four items of blood fat, reducing the level of total cholesterol, triglyceride and low-density lipoprotein and remarkably improving the level of high-density lipoprotein; 3, the prepared cannabis sativa peptide can obviously relieve non-alcoholic fatty liver disease caused by obesity and reduce liver fat accumulation; 4, the cannabis sativa peptide prepared by the invention can effectively relieve the occurrence and progress of obesity, reduce the weight change rate and reduce the obesity index, and has good lipid-lowering and weight-losing effects.

The invention belongs to the technical field of experimental animals, and particularly relates to application of reserpine in construction of animal models with normal high and low density lipoprotein and triglyceride values. The animal model construction method is minimally invasive, low in cost and good in reproducibility, has remarkable western medicine clinical biochemical index characteristics and a clear action mechanism, and can successfully and repeatedly establish an animal model with high and low density lipoprotein and normal triglyceride values. Conditions are created for clinical research on pathogenesis of related diseases, diagnosis and treatment of related diseases and screening, research and treatment of related disease mechanisms and drugs thereof, and good application prospects are achieved.

The invention provides a low density lipoprotein electrophoresis typing method and a gel electrophoresis separation column for electrophoresis typing, the gel electrophoresis separation column comprises a concentrated gel and a separation gel, the concentrated gel and the separation gel both comprise acrylamide, N, N-dimethacrylamide, cane sugar, glycerin and a Tris-HCl solution, the content of acrylamide in the separation gel is 1.42-1.53 times that of the concentrated gel, the content of the N, N-dimethacrylamide in the separation gel is 1.42-1.53 times that of the Tris-HCl solution, and the content of the N, N-dimethacrylamide in the separation gel is 1.42-1.53 times that of the Tris-HCl solution in the separation gel. And the content of N, N-bis (methacrylamide) in the separation gel is 1.41-1.52 times that in the concentrated gel. The electrophoresis typing method provided by the invention has the advantages of simplicity and convenience in operation, rapidness, high efficiency, high sensitivity, good resolution ratio and low cost.

The present invention discloses an anti - pyroptosis polypeptide and its application, relating to the technical field of biomedicine. The key points of its technical solution are: the anti - pyroptosis polypeptide is specifically used in the preparation of drugs for preventing and treating atherosclerosis. The amino acid sequence of the anti - pyroptosis polypeptide is shown as SEQ ID NO.1. The present invention firstly uses the anti - pyroptosis polypeptide to prepare drugs for treating and / or preventing atherosclerosis, and the effect of the anti - pyroptosis polypeptide in controlling atherosclerosis has been verified in cell models and animal models. In particular, the anti - pyroptosis polypeptide can enhance the viability of endothelial cells in the state of defective pyroptosis, significantly inhibit the expression of pyroptosis - related genes and proteins, and at the same time can reduce the levels of serum cholesterol and low - density lipoprotein in atherosclerotic mice, and reduce aortic lipid deposition and plaque formation. Moreover, when the anti - pyroptosis polypeptide of the present invention is used as a drug ingredient, it also has advantages such as low toxicity, small molecular weight, low immunogenicity and high druggability.

The invention discloses an application of clofampol in preparation of a medicine for preventing and / or treating non-alcoholic fatty liver disease, and belongs to the technical field of medicines. It is found that the clofamprol can reduce the liver index, effectively improve liver lipid metabolism disorder, inhibit hepatic cell fatty degeneration, inflammatory response and fibrosis processes, reduce the level of alanine transaminase, aspartic transaminase, total bilirubin, triglyceride and low-density lipoprotein, improve the level of albumin and high-density lipoprotein, and inhibit liver cell fatty degeneration, inflammatory response and fibrosis processes. Therefore, effective treatment on the non-alcoholic fatty liver is realized.

The invention discloses application of intestinal flora metabolite reuterin in preparation of a medicine for relieving or treating atherosclerosis, and relates to the technical field of medicine. The reuterin can reduce the blood sugar level, the total cholesterol level and the low-density lipoprotein cholesterol level, reduce liver lipid deposition, improve liver fatty degeneration, promote growth of beneficial bacteria, inhibit proliferation of potential harmful bacteria and inhibit cell penetration and uptake of low-density lipoprotein in endothelial cells. According to the application, the fact that the reuterin can be used for relieving or treating the atherosclerosis is disclosed for the first time, a new direction is provided for treating the atherosclerosis, and experiments show that the reuterin does not cause adverse effects on liver and kidney functions of mice after being used for a long time, and shows that the reuterin has good biological safety.